Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines
- 21 February 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 28 (5), 2485-2498
- https://doi.org/10.1007/s00520-019-05170-9
Abstract
Purpose To update the clinical practice guidelines for the use of growth factors and cytokines for the prevention and/or treatment of oral mucositis (OM). Methods A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. The findings were added to the database used to develop the 2014 MASCC/ISOO clinical practice guidelines. Based on the evidence level, the following guidelines were determined: recommendation, suggestion, and no guideline possible. Results A total of 15 new papers were identified within the scope of this section and were merged with 51 papers that were reviewed in the previous guidelines update. Of these, 14, 5, 13, 2, and 1 were randomized controlled trials about KGF-1, G-CSF, GM-CSF, EGF, and erythropoietin, respectively. For the remaining agents there were no new RCTs. The previous recommendation for intravenous KGF-1 in patients undergoing autologous hematopoietic stem cell transplantation (HSCT) conditioned with high-dose chemotherapy and TBI-based regimens is confirmed. The previous suggestion against the use of topical GM-CSF for the prevention of OM in the setting of high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation remains unchanged. Conclusions Of the growth factors and cytokines studied for the management of OM, the evidence supports a recommendation in favor of KGF-1 and a suggestion against GM-CSF in certain clinical settings.This publication has 94 references indexed in Scilit:
- Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical considerationThe Journal of Experimental Medicine, 2013
- Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patientsSupportive Care in Cancer, 2012
- Phase III Comparison of Standard Doxorubicin and Cyclophosphamide Versus Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer: SWOG 0012Journal of Clinical Oncology, 2011
- Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients with head and neck malignanciesEuropean Journal of Cancer Care, 2009
- Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositisAnnals of Oncology, 2008
- Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)Blood, 2006
- Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantationSupportive Care in Cancer, 2006
- Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experienceSupportive Care in Cancer, 2006
- Palifermin for Oral Mucositis after Intensive Therapy for Hematologic CancersThe New England Journal of Medicine, 2004
- Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trialEuropean Journal of Cancer, 2001